Australian health, nutrition and wellness company Eve Investments announced that its subsidiary Meluka Australia has completed the manufacture of a second order from China for 21,000 units of its raw honey.
Meluka Australia has been attracting overwhelming interest for its native honey range following its launch on Yandi Biotech’s online portal in China in mid-May.
In addition to completing the manufacture of this second honey purchase order at its Alstonville facility in Northern NSW, the company commenced the maiden production run of 57,600 units of its branded tea tree oil which is expected to be shipped to China in early July.
Meluka Australia has also registered strong interest for its raw honey probiotic concentrate following the launch of this product in March. Eve Investments said the manufacture of 20,000 units of raw honey probiotic concentrate for the initial target markets of Australia and the United States is due for completion in July, with the product to be rolled out in other markets in the coming months.
Managing Director Bill Fry said the growing sustained interest from China for the company’s diversified honey and tea tree oil offerings prompted EVE Investments to accelerate manufacturing operations as it looks to continue to deliver growth.
“Eve Investments continues to deliver strong sales growth as manufacturing operations continue to ramp up and support the business across our diversified honey and tea tree oil product range in Australia and abroad,” Mr Fry said.
“Commercial discussions are currently underway for the next series of orders, underlining the appetite for our premium tea tree oil and honey product offerings.
“We are buoyed by the progress of our manufacturing operations and sales pipeline during what have been challenging market conditions and look forward to keeping the market updated of our progress.”
Image credit: https://melukaaustralia.com.au/